ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03160339
Recruitment Status : Terminated (Sponsor Decision)
First Posted : May 19, 2017
Last Update Posted : June 18, 2018
Sponsor:
Collaborator:
Walter Reed Army Institute of Research (WRAIR)
Information provided by (Responsible Party):
PaxVax, Inc.

Brief Summary:
PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine [A549 Cells], Live, Oral) is an investigational vaccine in development for the indication of active immunization against adenovirus infection. The primary goals of this Phase 1 study are to evaluate safety, pharmacodynamics (viral shedding), and immunogenicity of PXVX0047.

Condition or disease Intervention/treatment Phase
Adenoviral Infection Biological: PXVX0047 Vaccine Biological: Teva Ad4/Ad7 Vaccine Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A Phase 1 Two-Arm, Randomized, Double-blind, Active-controlled Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine [A549 Cells], Live, Oral)
Actual Study Start Date : May 1, 2017
Actual Primary Completion Date : November 27, 2017
Actual Study Completion Date : November 27, 2017

Arm Intervention/treatment
Experimental: PXVX0047 treatment group
Subjects will receive PXVX0047 vaccine and Teva Placebo-to-Match
Biological: PXVX0047 Vaccine
PXVX0047 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in PXVX 0047 are unattenuated strains propagated in A549 human adenocarcinomic alveolar basal epithelial cells.

Active Comparator: Teva Ad4/Ad7 treatment group
Subjects will receive Teva Ad4/Ad7 vaccine and PXVX0047 Placebo-to-Match
Biological: Teva Ad4/Ad7 Vaccine
Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in Teva Ad4/Ad7 are unattenuated strains propagated in WI-38 human diploid fibroblast cells.




Primary Outcome Measures :
  1. Evaluate safety and tolerability of PXVX0047 by documenting the incidence of severity of solicited adverse events [ Time Frame: From Day 1 through Day 15 ]
    Incidence of severity of solicited adverse events include abdominal pain, nausea, vomiting, diarrhea, cough, nasal congestion, dyspnea, sore throat, headache, fever fatigue chills myalgia, arthralgia

  2. Evaluate the safety and tolerability of PXVX0047 by documenting the incidence and severity of adverse events that are not solicited. [ Time Frame: From Day 1 through Day 29 ]
    Unsolicited adverse events include clinical significant laboratory abnormalities

  3. Evaluate the induction of anti-Ad4 neutralizing activity by measuring the Ad4 and Ad7 seroconversion rate [ Time Frame: From Day 1 to Day 29 ]
    The Ad4 seroconversion rate is defined as the percent of subjects seroconverted (i.e. with a 4-fold or greater rise over baseline in neutralizing antibody titer) to Ad4 as determined by cytopathic-effect (CPE)-based assay

  4. Evaluate the induction of anti-Ad7 neutralizing activity by measuring the Ad7 seroconversion rate [ Time Frame: From Day 1 to Day 29 ]
    The Ad7 seroconversion rate is defined as the percent of subjects seroconverted (i.e. with a 4-fold or greater rise over baseline in neutralizing antibody titer) to Ad7 as determined by cytopathic-effect (CPE)-based assay


Secondary Outcome Measures :
  1. Evaluate the pharmacodynamics of PXVX0047 by measuring the shedding of Ad4 viruses via the GI tract [ Time Frame: Days 4, 8, 15, 22, and 29 ]
    Shedding of Ad4 via the GI tract, as assessed by rectal swabs

  2. Evaluate the pharmacodynamics of PXVX0047 by measuring the shedding of Ad7 viruses via the GI tract [ Time Frame: Days 4, 8, 15, 22, and 29 ]
    Shedding of Ad7 via the GI tract, as assessed by rectal swabs

  3. Evaluate the pharmacodynamics of PXVX0047 by measuring the shedding of Ad4 viruses via the respiratory tract [ Time Frame: Days 4, 8, 15, 22, and 29 ]
    Shedding of Ad4 via the respiratory tract, as assessed by throat swabs.

  4. Evaluate the pharmacodynamics of PXVX0047 by measuring the shedding of Ad7 viruses via the respiratory tract [ Time Frame: Days 4, 8, 15, 22, and 29 ]
    Shedding of Ad7 via the respiratory tract, as assessed by throat swabs.

  5. Evaluate the pharmacodynamics of PXVX0047 by measuring the presence of Ad4 viremia [ Time Frame: Days 4, 8, 15, 22, and 29 ]
    Presence of Ad4 viremia in the blood

  6. Evaluate the pharmacodynamics of PXVX0047 by measuring the presence of Ad7 viremia [ Time Frame: Days 4, 8, 15, 22, and 29 ]
    Presence of Ad7 viremia in the blood

  7. Evaluate the immunogenicity of PXVX0047 by measuring Ad4 seroconversion rates [ Time Frame: Through Day 57 ]
    The Ad4 seroconversion rates, measured independently, determined by luciferase and CPE-based assays

  8. Evaluate the immunogenicity of PXVX0047 by measuring Ad7 seroconversion rates [ Time Frame: Through Day 57 ]
    The Ad7 seroconversion rates, measured independently, determined by luciferase and CPE-based assays

  9. Evaluate the immunogenicity of PXVX0047 by measuring cumulative Ad4 seroconversion rates [ Time Frame: Through Day 57 ]
    The cumulative Ad4 seroconversion rates, measured independently, where cumulative seroconversion through a particular visit is defined as having seroconverted at or prior to that visit.

  10. Evaluate the immunogenicity of PXVX0047 by measuring cumulative Ad7 seroconversion rates [ Time Frame: Through Day 57 ]
    The cumulative Ad7 seroconversion rates, measured independently, where cumulative seroconversion through a particular visit is defined as having seroconverted at or prior to that visit.

  11. Evaluate the immunogenicity of PXVX0047 by measuring geometric mean titer [ Time Frame: Through Day 57 ]
    The geometric mean titer (GMT) of neutralizing antibodies to Ad4, measured independently

  12. Evaluate the immunogenicity of PXVX0047 by measuring geometric mean titer [ Time Frame: Through Day 57 ]
    The geometric mean titer (GMT) of neutralizing antibodies to Ad7, measured independently

  13. Evaluate the immunogenicity of PXVX0047 by measuring the fold-rise over baseline of neutralizing antibodies to Ad4 viruses [ Time Frame: Through Day 57 ]
    The fold-rise over baseline in neutralizing antibodies to Ad4, measured independently

  14. Evaluate the immunogenicity of PXVX0047 by measuring the fold-rise over baseline of neutralizing antibodies to Ad7 viruses [ Time Frame: Through Day 57 ]
    The fold-rise over baseline in neutralizing antibodies to Ad7, measured independently

  15. Evaluate the immunogenicity of PXVX0047 by measuring the cellular immune responses to Ad4 viruses [ Time Frame: At Days 29 and 57. ]
    The cellular immune responses to Ad4, measured independently

  16. Evaluate the immunogenicity of PXVX0047 by measuring the cellular immune responses to Ad7 viruses [ Time Frame: At Days 29 and 57. ]
    The cellular immune responses to Ad7, measured independently



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female
  • Age 18 to 35
  • Seronegative for Ad4 and Ad7 by CPE-based assay
  • (if female of childbearing potential) Using an acceptable method of contraception
  • If male, subject agrees to use a highly effective method of contraception with female sexual partners of childbearing potential
  • Able and willing to provide informed consent for study participation

Exclusion Criteria:

  • Current acute febrile illness
  • Current acute gastrointestinal illness
  • Clinically significant cardiac, respiratory, or gastrointestinal disease
  • (if female of childbearing potential) Pregnant or nursing, or who plan to become pregnant or nurse during the study
  • Persons with occupations which may create an increased risk of transmission of vaccine virus (including but not limited to health care workers, child or elderly care providers, food handlers or preparers) who also have expected occupational contact with children less than 7 years of age, pregnant or nursing women, women of childbearing potential not using an acceptable method of contraception, or chronically ill or immunosuppressed individuals through Day 29.
  • Expected household contact with children less than 7 years of age, pregnant or nursing women, women of childbearing potential not using an acceptable method of contraception, or chronically ill or immunosuppressed individuals through Day 29.
  • Laboratory evidence of infection with Hepatitis B/C or HIV.
  • History of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine.
  • Inability to swallow capsules or tablets whole without chewing or crushing.
  • Immunosuppressed individuals, including those treated or planned to be treated with systemic immunosuppressive medications within the 30 days prior to enrollment through 30 days after study treatment.
  • Concomitant or planned use of other vaccines, investigational agents, cidofovir, ribavirin, or medications expected by the Investigator to have antiviral activity against adenovirus within 30 days prior to enrollment through Day 29.
  • Any other condition that, in the opinion of the Investigator, creates an unacceptable risk to the subject.
  • Any other condition that, in the opinion of the Investigator, may interfere with the conduct of the study or the validity of the data.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03160339


Locations
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
United States, Vermont
University of Vermont Medical Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
PaxVax, Inc.
Walter Reed Army Institute of Research (WRAIR)

Responsible Party: PaxVax, Inc.
ClinicalTrials.gov Identifier: NCT03160339     History of Changes
Other Study ID Numbers: PXVX-AD-047-001
First Posted: May 19, 2017    Key Record Dates
Last Update Posted: June 18, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Vaccines
Immunologic Factors
Physiological Effects of Drugs